Is it Possible to Predict High-Risk Patients in Acute Pulmonary Embolism with Systemic Immune-Inflammation Index?

Yıl 2022, , 101 - 105, 30.12.2022

Murat Duyan , Ali Sarıdaş , Nafis Vural

https://doi.org/10.55994/ejcc.1193320

Cited By: 3

Öz

Background: Acute pulmonary embolism (APE) is a cardiovascular emergency that has a high morbidity and mortality probability. The aim of this study is to investigate the clinical value of the systemic immune inflammation index (SII) in predicting high-risk patients admitted to the emergency department with a diagnosis of Acute pulmonary embolism (APE).
Materials and Methods: This clinical study, which was conducted according to a cross-sectional study design, included 193 patients diagnosed with APE who presented to the emergency department of a tertiary hospital. According to the guideline, patients with Pulmonary Embolism Severity Index (PESI) class III–V or sPESI ≥I were identified as high risk. ROC (Area Under the Curve) analysis was used to determine the cut-off in predicting high-risk APE.
Results: In our research, 71 of the patients had high-risk APE. In detecting high-risk APE, SII was found to have excellent diagnostic power (AUC: 0.84), while neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and monocyte to lymphocyte (MLR) were found to have acceptable diagnostic power (AUC: 0.76-0.78), red cell distribution width (RDW) to lymphocyte (RLR) was of fair diagnostic power (AUC: 0.68).
Conclusion: We have shown that SII can be a valuable and useful potential biomarker to identify high-risk patients in patients with APE. We also found that MLR and RLR are biomarkers that can be used to predict severe APE.

Anahtar Kelimeler

Acute pulmonary embolism, the severity of pulmonary embolism, systemic immune inflammation index, monocyte to lymphocyte ratio, RDW to lymphocyte ratio

Destekleyen Kurum

The authors declare no conflict of interest or any financial support.

Proje Numarası

The authors declare no any financial support.

Kaynakça

• 1. Konstantinides S V., Meyer G, Bueno H, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.
• 2. Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nat Rev Dis Prim 2015 11. 2015;1(1):1-17.
• 3. Zhou XY, Ben SQ, Chen HL, Ni SS. The prognostic value of pulmonary embolism severity index in acute pulmonary embolism: A meta-analysis. Respir Res. 2012;13(1):1-12. 4. Kucher N, Goldhaber SZ. Risk stratification of acute pulmonary embolism. Semin Thromb Hemost. 2006;32(8):838-847.
• 5. Jiménez D, Kopecna D, Tapson V, et al. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med. 2014;189(6):718-726.
• 6. Zee RYL, Glynn RJ, Cheng S, Steiner L, Rose L, Ridker PM. An Evaluation of Candidate Genes of Inflammation and Thrombosis in Relation to the Risk of Venous Thromboembolism. Circ Cardiovasc Genet. 2009;2(1):57-62.
• 7. Chung T, Connor D, Joseph J, et al. Platelet activation in acute pulmonary embolism. J Thromb Haemost. 2007;5(5):918-924. 8. Jo JY, Lee MY, Lee JW, Rho BH, Choi W Il. Leukocytes and systemic inflammatory response syndrome as prognostic factors in pulmonary embolism patients. BMC Pulm Med. 2013;13(1):1-8. 9. Ince LM, Weber J, Scheiermann C. Control of leukocyte trafficking by stress-associated hormones. Front Immunol. 2019;10(9):3143.
• 10. Köse N, Yıldırım T, Akın F, Yıldırım SE, Altun İ. Prognostic role of NLR, PLR, and LMR in patients with pulmonary embolism. Bosn J Basic Med Sci. 2020;20(2):248.
• 11. Ates H, Ates I, Kundi H, Yilmaz FM. Diagnostic validity of hematologic parameters in evaluation of massive pulmonary embolism. J Clin Lab Anal. 2017;31(5).
• 12. Celik A, Ozcan IT, Gündes A, et al. Usefulness of admission hematologic parameters as diagnostic tools in acute pulmonary embolism. Kaohsiung J Med Sci. 2015;31(3):145-149.
• 13. Phan T, Brailovsky Y, Fareed J, Hoppensteadt D, Iqbal O, Darki A. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism. Clin Appl Thromb. 2020;26.
• 14. Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261-6272.
• 15. Diao P, Wu Y, Li J, et al. Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection. J Transl Med. 2018;16(1):1-11.
• 16. Jomrich G, Gruber ES, Winkler D, et al. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. J Gastrointest Surg. 2020;24(3):610-618.
• 17. Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract. 2010;15(5):625-632.
• 18. Li S, Liu K, Gao Y, et al. Prognostic value of systemic immune-inflammation index in acute/subacute patients with cerebral venous sinus thrombosis. Stroke Vasc Neurol. 2020;5(4):368-373.
• 19. Xue J, Ma D, Jiang J, Liu Y. Diagnostic and Prognostic Value of Immune/Inflammation Biomarkers for Venous Thromboembolism: Is It Reliable for Clinical Practice? J Inflamm Res. 2021;14:5059-5077.
• 20. Peng J, Wang H, Zhang L, Lin Z. Construction and efficiency analysis of prediction model for venous thromboembolism risk in the elderly after hip fracture. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021;46(2):142-148.
• 21. Gok M, Kurtul A. A novel marker for predicting severity of acute pulmonary embolism: systemic immune-inflammation index. Scand Cardiovasc J. 2021;55(2):91-96.
• 22. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5-14.
• 23. Telo S, Kuluöztürk M, Deveci F, Kirkil G. The relationship between platelet-to-lymphocyte ratio and pulmonary embolism severity in acute pulmonary embolism. Int Angiol. 2019;38(1):4-9.
• 24. Ozcan Cetin EH, Cetin MS, Canpolat U, et al. Platelet-to-lymphocyte ratio as a novel marker of in-hospital and long-term adverse outcomes among patients with acute pulmonary embolism: A single center large-scale study. Thromb Res. 2017;150:33-40.
• 25. Kundi H, Balun A, Cicekcioglu H, Cetin M, Kiziltunc E, Cetin ZG, et al. The relation between platelet-to-lymphocyte ratio and Pulmonary Embolism Severity Index in acute pulmonary embolism. Heart & Lung. 2015;44(4):340-343.
• 26. Hutterer GC, Sobolev N, Ehrlich GC, et al. Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma. J Clin Pathol. 2015;68(5):351-355.
• 27. Ertem AG, Yayla C, Acar B, et al. Relation between lymphocyte to monocyte ratio and short-term mortality in patients with acute pulmonary embolism. Clin Respir J. 2018;12(2):580-586.
• 28. Ozsu S, Abul Y, Gunaydin S, Orem A, Ozlu T. Prognostic value of red cell distribution width in patients with pulmonary embolism. Clin Appl Thromb. 2014;20(4):365-370.
• 29. Wu J, Zhang X, Liu H, Guo N, Pan Q, Wang Y. RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clin Biochem. 2019;63:24-31.